1.31

2.34% 0.03

Sellas Life Sciences Group Inc (SLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SLS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.28

Offen:

$1.27

24-Stunden-Volumen:

1.15M

Relative Volume:

0.49

Marktkapitalisierung:

$103.57M

Einnahmen:

Nettoeinkommen (Verlust:

$-37.34M

KGV:

-0.9632

EPS:

-1.36

Netto-Cashflow:

$-36.91M

1W Leistung:

+18.02%

1M Leistung:

+15.93%

6M Leistung:

+4.80%

1J Leistung:

-7.09%

1-Tages-Spanne:

$1.261

$1.33

1-Wochen-Bereich:

$1.11

$1.36

52-Wochen-Spanne:

$0.772

$1.84

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Firmenname

Sellas Life Sciences Group Inc

Sektor

Healthcare (1151)

Branche

Biotechnology (660)

Telefon

(646) 200-5278

Adresse

7 TIMES SQUARE, NEW YORK, NY

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

SLS's Discussions on Twitter

Vergleichen Sie SLS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SLS Sellas Life Sciences Group Inc	1.31	103.57M	0	-37.34M	-36.91M	-1.36
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-07-21	Eingeleitet	Cantor Fitzgerald	Overweight
2018-11-01	Eingeleitet	Oppenheimer	Outperform
2018-04-02	Eingeleitet	H.C. Wainwright	Buy
2018-03-19	Hochstufung	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

Apr 09, 2025

SELLAS reports promising AML treatment trial results - Investing.com

Apr 09, 2025

Apr 08, 2025

SELLAS posts mid-stage trial win for leukemia drug (SLS:NASDAQ) - Seeking Alpha

Apr 08, 2025

Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up - MarketScreener

Apr 08, 2025

Sellas Life Sciences Shares Gains On Positive Cohort 3 Phase 2 Results For SLS009 - Nasdaq

Apr 08, 2025

SELLAS reports promising AML treatment trial results By Investing.com - Investing.com India

Apr 08, 2025

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewswire

Apr 08, 2025

Breakthrough: New Leukemia Drug Shows 8.8-Month Survival vs 2.5-Month Standard - Stock Titan

Apr 08, 2025

Apr 05, 2025

Critical Review: SELLAS Life Sciences Group (NASDAQ:SLS) vs. CV Sciences (OTCMKTS:CVSI) - Defense World

Apr 05, 2025

Apr 02, 2025

Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Apr 02, 2025

Mar 31, 2025

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha

Mar 31, 2025

Mar 28, 2025

Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World

Mar 28, 2025

Mar 27, 2025

Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks

Mar 27, 2025

Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025

Mar 21, 2025

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 21, 2025

Mar 20, 2025

SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq

Mar 20, 2025

SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView

Mar 20, 2025